【摘要】目的 研究乙酰肝素酶在子宫内膜癌组织中的表达及其临床意义。方法 采用免疫组化SP法检测43例子宫内膜癌组织、31例子宫内膜增生症组织及20例正常子宫内膜组织中乙酰肝素酶蛋白的表达。结果 乙酰肝素酶在正常子宫内膜组织、增生症组织及子宫内膜癌中的表达呈上升趋势，3组间表达有显著性差异(P<0.01)。在子宫内膜癌中，乙酰肝素酶表达与手术病理分期(FIGO)(P<0.05)、组织病理学分级(P<0.05)和肌层浸润程度(P<0.01)具有明显相关性。结论 乙酰肝素酶可能与子宫内膜癌的发生发展有关，有望作为判断子宫内膜癌生物学行为和预后的参考指标。
【关键词】 子宫内膜癌;免疫组化;乙酰肝素酶
Expression of heparanase in endometrial carcinoma
and its clinical significance
Xue Ruijuan, Yang Hua, Xue Xiaoping, Yang Ting, Liu Xinyu
(1. Department of Gynecology and Obstetrics, the Second Affiliated Hospital,Medical School of Xian Jiaotong University, Xian 710004; 2. Xian University of Finance and Economics, Xian 710061, China)
ABSTRACT: Objective To study the expression and clinical significance of heparanase in endometrial carcinoma. Methods Altogether 43 cases of endometrial carcinoma, 31 cases of endometrial hyperplasia and 20 cases of normal endometrium were detected for the expression of heparanase by means of immunohistochemical SP. Results The heparanase expression showed an ascending tendency, with significant differences among normal endometrium, endometrial hyperplasia and endometrial carcinoma groups (P<0.01). In endometrial carcinoma, the expression of heparanase was significantly associated with FIGO stage (P<0.05), histological grade (P<0.05), and myometrium invasion (P<0.01). Conclusion Heparanase may play a role in endometrial carcinoma in regulation of tumorigenesis and progression, and may be used as a useful marker of the biological behavior of endometrial carcinoma and as a prognosis factor for patients with endometrial carcinoma.
KEY WORDS: endometrial carcinoma; immunohistochemistry; heparanase
子宫内膜癌(endometrial carcinoma, EC)是妇女常见的恶性肿瘤之一，占女性生殖道恶性肿瘤20%-30%。近年来其发生呈年轻化趋势[1]。肿瘤细胞与细胞外基质(extracellular matrix, ECM)的黏附性及向基质侵袭是肿瘤发生转移的首要环节，也是肿瘤转移的重要条件。乙酰肝素酶(heparanase, Hpa)是目前在哺乳动物体内发现的唯一一种能切割细胞外基质和基底膜中硫酸乙酰肝素多聚糖蛋白(heparan sulfate proteogl
[1] [2] [3] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 妇产科论文 >> 正文